Non-Hodgkin lymphomas (NHLs) represent the fifth most frequent cancer (Jemal et al, 2009) . Diffuse large B-cell lymphoma (DLBCL) constitutes the most common subtype, accounting for 25-30% of adult NHLs in Western countries, and is characterized by heterogeneous histopathological, clinical and biological features (Armitage, 2007; Lenz & Staudt, 2010) . DLBCL represents a potentially curable disease when treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d) for 6-8 cycles. Nevertheless, the progression-free survival (PFS) in elderly patients is still below 55% and in younger patients does not exceed 85%.
Gene expression profiling (GEP) patterns and genomic aberrations have been identified to have an impact on the clinical course of DLBCL patients treated with CHOP (Lenz et al, 2008a; Lenz & Staudt, 2010) . Differently from GEP data (Lenz et al, 2008b) , no information is available on the prognostic impact of genomic aberrations detected using high resolution single nucleotide polymorphism (SNP) array in DLBCL patients treated with R-CHOP.
In this study, we analysed the impact of recurrent aberrations revealed by a high-density genome wide SNP-based array on clinical outcome in DLBCL patients treated with R-CHOP-21.
Materials and methods

Tumour panel
DNA was extracted from 166 frozen tumour biopsies of DLBCL, taken at diagnosis as previously described Rinaldi et al, 2010) . Cases were selected for the study based upon the availability of frozen material, and were required to have a fraction of malignant cells in the pathological specimen representing >70% of overall cellularity as determined by morphological and immunophenotypic studies. Cases of primary mediastinal large B-cell lymphoma, human immunodeficiency virus-related DLBCL and posttransplant DLBCL were excluded. Therapy was R-CHOP21 in 137 cases (13 with no follow-up data available) and other than R-CHOP21 in 14 (four, R-CHOP14; two, CHOP; four high-dose chemotherapy; four, other), and unknown in 15. As previously reported Rinaldi et al, 2010) , the distinction of DLBCL cases in germinal centre B-cell-like (GCB) or in non-GCB, was available in 110 cases: assessed in 52 cases by immunohistochemistry according to the algorithm of Hans et al (2004) (25 GCB, and in 58 by GEP (Lenz et al, 2008b ) (31 GCB, 27 non-GCB). All patients provided informed consent in accordance with the hospital's institutional review board and the Declaration of Helsinki. The study was approved by the Bellinzona Ethics Committee.
SNP array-CGH analysis and data mining
DNA samples were analysed using the GeneChip Human Mapping 250K NspI (Affymetrix, Santa Clara, CA, USA), as previously described Rinaldi et al, 2010) . Data acquisition was performed using the GeneChip operating software (GCOS, Affymetrix, Santa Clara, CA, USA) version 1.4 and genotyping analysis software (GTYPE, Affymetrix, Santa Clara, CA, USA) version 4.1. Genotype calls were calculated using the BRLMM algorithm (Bayesian Robust Linear Model with Mahalanobis distance classifier). Mapping data for probes were derived from the National Center for Biotechnology Information (NCBI) Human Genome Build 36, as provided by Affymetrix. The modified Bayesian Piecewise Regression (mBPCR) method (Rancoita et al, 2009 ) was used to estimate the copy number (CN) starting from raw CN values obtained with Affymetrix CNAT 4AE01 using a Gaussian bandwidth of 0 Kb and 46 Caucasian normal female samples of the HapMap Project as reference samples. After normalization of each profile to a median log2-ratio of zero, thresholds for loss and gain defined as six times the median absolute deviation symmetrically around zero with an associated P value lower than <0AE001 after Bonferroni multiple test correction. Loss of heterozygosity (LOH) profiles were obtained applying the method with haplotype correction for tumour-only LOH inference available in the dchip software (Beroukhim et al, 2006) using as reference the 60 CEPH (Centre d'Etude du Polymorphisme Humain) parents of the HapMap Project and computing the allele A frequency from the data. Figure S1 shows examples of the genomic lesions with raw and inferred CN, and LOH estimate. Frequency plots for DNA gains, DNA losses and LOH were calculated from mBPCR segmented CN data, thresholded for gain or loss or for LOH, without removing known copy number variations (CNV). All the 166 DLBCL profiles were used to identify the minimal recurrent alterations that are supposed to contain loci relevant for the tumour, following the algorithm developed by Lenz et al (2008a) . Four distinct types of minimal common regions (MCR) were defined: short recurrent abnormality (SRA), long recurrent abnormality (LRA), abnormal chromosome arm (ACA) and abnormal whole chromosome (AWC). In MCR frequencies, patients carrying a lesion contained in both an SRA and in an LRA were counted for both types of MCR. For MCR occurring in at least 15% of cases, differences in frequencies between subgroups were evaluated using a Fisher's exact test followed by multiple test correction (MTC). MCRs were compared with the Database of Genomic Variants (http://projects.tcag.ca/variation/): regions showing an overlap above 80% between probes and known CNV were considered bona fide CNV.
In order to identify biological subgroups according to the genetic profile, unsupervised clustering was performed using the non-negative matrix factorization (NMF) algorithm on all 166 cases (Lee & Seung, 2001; Chigrinova et al, 2010) . The best rank was chosen based upon the cophenetic correlation for the consensus matrix.
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 2008 web-accessible program (Huang da et al, 2009) was used to map genes contained within MCR, retrieved using the web-accessible Galaxy (http://galaxy. psu.edu/) (Giardine et al, 2005) , to KEGG and Biocarta Pathways, and statistically examine the enrichment of gene members for each pathway.
Raw data will be available at the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) database.
Gene expression
Previously published gene expression data (Lenz et al, 2008b) , obtained using the affymetrix genechip U133 plus 2.0 (Affymetrix, Santa Clara, CA, USA), were available for 54/166 cases. CEL files were imported in Partek Genomics Suite 6AE4 (Partek, St Louis, MO, USA). Signal intensities were normalized by Partek RMA. Statistical differences were calculated by analysis of variance (anova) analysis and the genes with a P value <0AE005 were analysed for enrichment of KEGG and Biocarta pathways using DAVID 2008 web-accessible program (Huang da et al, 2009) .
To classify our samples according to the DLBCL consensus clusters described by Monti et al (2005) , we trained a Naive Bayes classifier based on the 176 labelled samples from the original publication and 2117 probe-sets using the 'naiveBayes' function in the 'e1071' R-package. Then, this classifier was applied on our normalized GEP values to infer the best associated cluster: 'oxidative phosphorylation,' (OxPhos), 'B-cell receptor/ proliferation,' (BCR) and 'host response' (HR) clusters.
Statistical analysis
Response to R-CHOP-21, overall survival (OS), PFS and disease-free survival (DFS), defined according to the criteria of Cheson et al (2007) , were evaluated in the 124/166 cases treated with R-CHOP21 and with available follow-up data. Survival probabilities were plotted according to the KaplanMeier method. The impact of the MCR on the clinical outcome was determined with the log-rank test (Mantel & Haenszel, 1959) . To control false positive rate the BenjaminiHochberg-method (Q-value) was performed. Internal validation was quantified by calculating the Harrell concordance index (C-index) (Harrell, 2001; Kim et al, 2004; Hoster et al, 2008) . A C-index of 0AE5 indicates that outcomes are completely random, whereas a C-index of 1 indicates that the model is a perfect predictor. We used the bootstrap procedure as implemented in the 'validate' functions of the Design library in R (R Development Team 2009), which allowed for computation of an unbiased estimate of the C-index. We used 500 bootstrap samples. To identify MCR with an independent DLBCL Subgroups and Genomic Aberrations ª 2010 Blackwell Publishing Ltd, British Journal of Haematology, 151, 221-231 impact on survival, we used a Cox proportional-hazard model with a stepwise selection of the significant variables. MCR occurring in at least 5% of the patients and with a significant impact in univariate analysis, and the single factors of the International Prognostic Index (IPI) for aggressive lymphomas were included in the model. A P-value below 0AE05 was considered as statistically significant. Chi-square test was used to compare differences in clinical parameters among the different NMF subgroups previously identified. Statistical analyses on clinical data were performed with spss 17AE0AE1 (SPSS, Chicago, IL, USA) and R statistical package (R Development Team 2009).
Results
The frequencies of gains, losses and of LOH in 166 DLBCL samples are shown in Fig 1. The following MCRs were identified: 58 gains, 47 losses, 54 LOH, five recurrent amplifications and seven homozygous deletions (Table SI) .
Amplifications occurred at 2p16AE1 (7/166, 4%), 2p15 (3/166, 2%), 9p24AE3-p21AE3 (3/166, 2%), 13q32AE1 (2/166, 1%) and 19q13AE3 (2/166, 1%). Known oncogenes and lymphoma genes were present in 3/5 lesions: BCL11A and REL (2p16), JAK2 (9p), SPIB (19q). The 2p15 included C2orf86, MDH1, UGP2. The 13q32AE1 region contained DNAJC3, HS6ST3, OXGR1, UGGT2 and mapped approximately 4 Mb telomeric to the transforming MIR17-92 cluster.
Homozygous deletions occurred at 3p14AE2 (2/166, 1%), 6q23AE3-q24AE1 (2/166, 1%), 9p21AE3 (5/166, 3%), 10q23AE31 (2/ 166, 1%), 14q11AE2 (3/166, 2%), 15q11AE2 (2/166, 1%), and 19p13AE3-p13AE2 (2/166, 1%). Known tumour suppressor genes were included in 4/7 of these these MCRs: FHIT (3p14AE2), TNFAIP3 (A20) (6q23AE3), CDKN2A (9p21AE3) and FAS (10q23AE31). The 14q and 15q might be considered bona fide CNV because they had a total overlap with known CNV, although the first lesion is located within the T-cell receptor alpha locus (TRA@), and could be due to infiltrating normal T-cells or a T-cell rearrangement that occurred in the lymphoma B-cell (Fuschiotti et al, 2007) . The 15q deletion targeted OR4N4 and OR4M2, G-protein-coupled receptors, members of the olfactory receptor gene family. The deletion of the 19p13 region has not been previously reported and comprised a series of genes, including C3 (complement precursor 3), TNFSF9 and TNFSF14 (tumour necrosis factor ligand superfamily nine and 14).
Genomic regions and outcome in patients treated with R-CHOP-21 Table I shows the clinical features of 124/166 (75%) cases, treated with R-CHOP-21 and for whom follow-up data were available.
The rate of complete remissions (CR) was 81% (100/124), partial remissions (PR) 12% (15/124) and stable (SD) or progressive disease (PD) 7% (9/124). Among the complete responders, 27 (22%) eventually relapsed. After a median follow-up of 23 months (range, 1-123 months), the 3-year estimated OS was 88%, PFS 65% and DFS 71%. Figure S2 shows the frequency of CN changes and of LOH for the 100 patients who obtained a CR after R-CHOP-21 and for the 24 who did not. The following lesions were more frequent in the non-CR patients: del(8p) (21% vs. 5%; P = 0AE023), del(8p21AE2-p23AE1) (21% vs. 6%; P = 0AE036), del(15q11AE2) (8% vs. 0%; P = 0AE036) and LOH of 8p23AE1 (25% vs. 4%; P = 0AE003), 9p (12AE5% vs. 2/100, 2%; P = 0AE049) and 15q21AE3 (22% vs. 5%; P = 0AE019) (Table SI) .
Twenty regions showed a statistically significant impact on OS, PFS and/or DFS (Table II) .
Lesions with the strongest association with a worse outcome were deletions affecting the short arm of chromosome 8: del(8p23AE1) (P = 0AE002 , Fig 2) , del(8p) (P = 0AE01), and del(8p23AE1-21AE2) (P = 0AE012). The prognostic relevance of these aberrations was underlined by an internal validation which calculated the C-index corrected for over-fitting by a bootstrap procedure. The C-index values were 0AE64, and 0AE584, 0AE58.
Among the four homozygous deletions associated with a poor clinical outcome, two targeted known tumour suppressor genes: TNFAIP3 at 6q23AE3, and FAS at 10q23AE31. Two, at 14q11AE2 and 15q11AE2, occurred at bona fide CNV: TRA@ and OR4N4/OR4M2 respectively). Although statistically significant, there were only a few cases bearing the four recurrent homozygous deletions, making it impossible to ascertain their real impact on outcome.
In order to identify possible pathways affected by these genomic regions, we mapped the genes contained within MCRs to known biological pathways. Seven pathways appeared to be significantly enriched: natural killer cellmediated cytotoxicity, regulation of autophagy, antigen processing and presentation, Jak-STAT signalling pathway, Toll-like receptor signalling pathway, cytokine-cytokine receptor interaction and apoptosis (Table III) .
In order to evaluate whether the identified MCRs were independent prognostic factors for OS, PFS and DFS, we performed a multivariate Cox regression. From the IPI factors, only lactate dehydrogenase (OS, P = 0AE032 and PFS, P = 0AE002) and stage III/IV (PFS, P = 0AE017) influenced survival independently in the multivariate analysis. None of the regions retained significance in the multivariate analysis.
Lesions associated with del(8p23AE1)
We compared the pattern of genomic aberrations in patients with and without del(8p23AE1) to elucidate the possible biological significance of genomic losses at this locus. Cases with del(8p23AE1) presented several associated lesions (Table SII) . The highest statistical significance was observed for losses occurring on the long arm of chromosome 15 (50% vs. 10%; P = 0AE00004), on 17p (41% vs. 10%; P = 0AE0006), on 10q23AE33-q24AE1 (32%, vs. 7%; P = 0AE002) and for 11q gains (41%, vs. 11%; P = 0AE0009).
Unsupervised clustering
In order to identify subgroups of patients with different genetic lesions and with possible distinct clinical outcome, we performed unsupervised clustering using the NMF algorithm. The latter represents a relatively new algorithm, showing advantages in the analysis of arrayCGH over other unsupervised approaches . Five clusters were identified with distinct genetic profiles (Figs 3, and S3) , without a significant bias on geographic provenance. Cluster 1 consisted of 77/166 patients (46%). Their genetic profile was heterogeneous and few recurrent aberrations could be Due to the distinct genomic profiles we compared Cluster 1 versus Clusters 2 and 4 and Cluster 2 versus Cluster 4. Cluster 1 showed a lower percentage of older patients (P = 0AE068), a significantly higher rate of bone marrow (BM) involvement (16/57, 28% vs. 1/19, 5% and 2/24, 8%; P = 0AE008) and hepatitis C virus (HCV) infection (9/38, 24% vs. 1/12, 8% and 0/20; P = 0AE014). Clusters 2 and 4 showed differences in the number of patients with a high IPI-score (9/16, 56% vs. 7/26, 27%; P = 0AE057), and relapse rate (5/17, 29% vs. 2/25, 8%; P = 0AE068). We did not further analyse Clusters 3 and 5 (overall 23 patients).
Cluster 1 was not only characterized by a distinct genomic profile and different clinical features, such as high HCV infection and BM involvement, but, similar to Cluster 2, the outcome was relatively poor when compared to Cluster 4: high relapse rate (26%), 3-year estimated OS of 83%, 61% PFS and 66% DFS. Moreover, unlike Cluster 2 and 4, the PFS of Cluster 1 did not reach a plateau. The comparison of Cluster 2 and 4 showed a poorer DFS for Cluster two patients (P = 0AE048). After 5 years both Clusters 2 and 4 reached a plateau in OS, PFS and DFS. In Cluster 2, the 3-year estimate of OS was 80%, PFS 62% and DFS 67%, whereas in Cluster 4, the 3-year estimate of OS was 92%, PFS 84% and DFS 83% (Fig S4) .
The distribution of GCB or activated B-cell like (ABC) DLBCL, defined by GEP or by immunohistochemistry, did not present statistical differences among the five NMF clusters, although Cluster 4 consisted of mainly GCB (8/12, 67%), and Cluster 5 of ABC (7/10, 70%) (Fig S3) . The distribution of the DLBCL-consensus clusters OxPhos, BCR, and HR presented a statistically significant distribution of HR cases, which were almost all in NMF Cluster 1 (12/16, 75%; P = 0AE023) (Fig S3) .
A supervised analysis of the gene expression profile of Cluster 1 versus Clusters 2 and 4 identified 546 probes (P < 0AE005) ( Table SIII) . Genes of the T-cell receptor signalling pathway were the only significantly over-represented group of genes (P = 2 E)06; Q = 4 E)04). All 8/166 DLBCL cases described as T-cell rich were classified as Cluster 1. Fig S5 shows the pattern of genomic lesions in 98 cases according to HCV-status. Although no statistical significance could be demonstrated, the 12 HCV+ DLBCL cases appeared to have less recurrent aberrations than HCV-negative cases, in accordance with that observed in NMF clustering.
Discussion
We conducted this retrospective multi-centre study to explore the impact of unbalanced genomic aberrations, detected using a high-density genome wide-SNP-based array, on OS, PFS and DFS in a population of DLBCL patients treated with the standard regimen R-CHOP-21. Deletions affecting the short arm of chromosome 8 had the most significant impact on survival. Five subgroups of patients with different aberrations and clinical features were identified by unsupervised clustering.
A series of 171 recurrent lesions were identified, largely reflecting what has already been reported in DLBCL (Tagawa et al, 2005a; Lenz et al, 2008a; Lenz & Staudt, 2010) . The high resolution of the arrays allowed the detection of a discrete number of recurrent homozygous deletions, some targeting well known tumour suppressor genes, such as CDKN2A (9p21) or FAS (10q23AE31), and the more recently reported TNFAIP3 (Compagno et al, 2009) . A homozygous deletion affected 19p13, possibly overlapping that reported in mantle cell lymphoma (Tagawa et al, 2005b) . The lesion was still relatively large in size with several genes as possible targets, including C3, TNFSF9 and TNFSF14.
Twenty regions revealed a significant correlation with clinical outcome. In order to exclude a selection bias, we compared the observed clinical parameters to a previously published series of patients affected by DLBCL (Sehn et al, 2005) , showing that they were comparable and thus reflected the general population of DLBCL patients. Loss of genomic material in the short arm of chromosome 8, in particular at 8p23AE1, was associated with the most significant impact on OS, also confirmed by an internal validation by bootstrap. Moreover, the same region was more common among non responders. Del(8p) and loss of smaller regions of this chromosome arm were previously shown to be associated with poor characteristics and worse outcome in other lymphoid neoplasms (Martinez-Climent et al, 2001; RubioMoscardo et al, 2005a; Thelander et al, 2005; Forconi et al, 2008) . Losses of 17p (TP53, HIC1) and 15q (TP53BP1) were observed at a statistically higher prevalence in association with loss of 8p, suggesting that the possible poor outcome after R-CHOP-21 could be due to the concomitant deregulation of a series of genes mapped on different chromosomes. Indeed, genes involved in DNA repair and apoptosis are mapped in these regions and could all be inactivated in patients bearing these deletions: TNFRSF10A (TRAIL-R1) and TNFRSF10B (TRAIL-R2) (8p), TP53 and HIC1 (17p) and TP53BP1 (15q) (Rubio-Moscardo et al, 2005b; Young et al, 2007; Takeyama et al, 2008) , which are enriched among patients with a poor CR-rate. Interestingly, in DLBCL, loss of TP53 has been shown CHP, TNFRSF10C, FAS, PPP3CC, TNFRSF10B, TNFRSF10A,  TNFRSF10D,   0AE011  0AE273   Natural killer cell mediated cytotoxicity  CHP, IFNB1, IFNA6, IFNA8, SHC4, IFNA21, PPP3CC,  TNFRSF10B, IFNA7, IFNA17, IFNA2, IFNA16, IFNA5,  TNFRSF10C, IFNA4, FAS, IFNA1, IFNA10, TNFRSF10A, IFNA14,  TNFRSF10D ,
Regulation of autophagy  IFNA6, IFNA4, IFNA8, IFNA21, IFNA1, IFNA10, IFNA7, IFNA17,  IFNA14, IFNA5, IFNA16, IFNA2 1AE05 · 10
Jak-STAT signalling pathway IFNA6, IFNB1, IFNA8, IFNA21, JAK2, IFNA17, IFNA7, IFNA2, IFNW1, IFNA16, IFNA5, SPRED1, IFNA4, IFNA1, IFNA10, IFNA14
Toll-like receptor signalling pathway IFNA6, IFNB1, IFNA8, IFNA21, IFNA17, IFNA7, IFNA2, IFNA16, IFNA5, IFNA4, IFNA1, IFNA10, IFNA14
Antigen processing and presentation IFNA6, IFNA8, IFNA21, PDIA3, CTSB, IFNA17, IFNA7, IFNA2, IFNA16, IFNA5, IFNA4, IFNA1, IFNA10, B2M, IFNA14
Cytokine-cytokine receptor interaction IFNB1, IFNA6, IFNA8, IFNA21, TNFRSF10B, IFNA7, IFNA17, IFNA2, IFNW1, IFNA16, IFNA5, TNFRSF10C, IFNA4, FAS, IFNA1, IFNA10, TNFRSF10A, IFNA14, TNFRSF10D
For each pathway, genes mapped in the MCRs, and the level of statistical enrichment (P-value and Benjamini-multiple test corrected) are given. to correlate with low levels of TNFRSF10B (Young et al, 2007) , and loss of 8p is a frequent phenomenon in patients with chronic lymphocytic leukaemia with 17p loss, possibly identifying a subgroup of patients with an extremely poor outcome (Forconi et al, 2008) . Regarding TP53, in our series, loss of 17p13AE1 did not show any impact on the clinical outcome, similarly to that previously reported by Young et al (2007) , who showed a negative influence of TP53 mutations but not of the genomic loss on the clinical course in their series of DLBCL patients. Del(9p21AE3) had a negative impact on the response to treatment, albeit no apparent influence on survival was observed. These results are consistent with previous data reporting the unfavourable influence of this aberration on CHOP-treated DLBCL patients (Lenz et al, 2008a) .
DLBCL Subgroups and Genomic Aberrations
Functional annotation analysis and pathway mapping identified seven significantly enriched pathways among the genes of the regions with an impact on survival. Among the genes involved in these pathways were TNFRST10A/TNFRSF10B, FAS (natural killer mediated cytotoxicity and apoptosis) and JAK2 (JAK-STAT pathway). Both, TNFRST10A/TNFRSF10B and FAS are genes coding for proteins with a crucial role in regulation of cell death and are known to be involved in mechanisms of tumour escape (Khong & Restifo, 2002) . Therefore, loss of these genes in DLBCL strengthens the notion that both genes may play an important role in this disease. On the contrary, JAK2, a gene coding for a protein able to promote cell transformation by constitutive activation of the JAK-STAT pathway (Knoops et al, 2008) , was amplified. The specific role of this aberration in DLBCL is yet unclear, whereas it has been shown that JAK2 genomic gains are frequent in primary mediastinal large B-cell lymphoma and Hodgkin lymphoma, but they can occur also in DLBCL, more commonly among ABC-type (Lenz et al, 2008a) .
The relatively small number of cases bearing the lesions and the median follow-up of only 2 years might partially explain the fact that none of the 20 genomic markers remained as an independent prognostic marker when analysed in a multivariate analysis alongside the IPI factors.
The unsupervised NMF-clustering identified five clusters with distinct genetic profiles, and some with different clinical characteristics and distinct courses.
Cluster one patients were characterized by a heterogeneous genomic profile, lacking most recurrent lesions and displaying the worst long term outcome amongst the different clusters. These patients had a high rate of HCV infection and BM involvement and a slightly younger age. GEP and morphology data suggested that this cluster could represent DLBCL cases with a high content of normal infiltrating T-cells, which would partially explain the low rate of recurrent genomic aberrations due to a lower content of neoplastic cells. These data could delineate a DLBCL subtype with distinct clinical features and a high rate of inflammatory cells. Indeed, when we applied the DLBCL-consensus cluster classifier (Monti et al, 2005) to our DLBCL cases with available GEP, there was a statistically significant enrichment of Cluster 1 for HR-DLBCL. The latter subgroup of DLBCL has been described as having increased expression of T-cell molecules, and, when compared to other DLBCL cases, HR patients were significantly younger, had a higher incidence of BM involvement and a lack of the recurrent chromosomal translocations involving BCL2 or BCL6 (Monti et al, 2005) . Alternatively, we can speculate that, as we observed a high prevalence of HCV infection and because viruses can induce epigenetic transforming changes in human cells (Ferrari et al, 2009) , at least part of Cluster 1 DLBCL, as well of the HR cluster, might have developed mainly through epigenetic changes rather than genomic aberrations. In support of this hypothesis, in our series, HCV-positive DLBCL cases showed a tendency for a lower rate of genomic lesions, but the number of cases was small and only studies on micro-dissected lymphoma cells will provide final results.
Similar to Cluster 1, the outcome of the Cluster two patients was relatively poor. This subgroup was characterized by 1q gain, 3q gain, 1p, 6q and 17p losses. Conversely, Cluster four patients, mainly characterized by gains of chromosome 7 and 12, presented a good outcome. Among the remaining two clusters, Cluster 3 was characterized by losses of 6q, 9, and 11q gains, and a trend for a good outcome, whilst Cluster 5 (gains of 3q, 11q and 18q; losses of 6q, 8p, 9p, 15q and 17p) for a poor outcome. The distribution of cases according to the cell-of-origin did not show statistical differences, probably due to the small number of cases with GEP, but, as expected based upon their genomic profiles, Clusters 4 and 5 presented more GCB and ABC cases, respectively. These data, together with our previous experience with NMF , and the data reported using a model-based clustering (Shah et al, 2009) , strongly suggest that the application of new unsupervised clustering algorithm on large DLBCL arrayCGH datasets will provide important insights for sub-classifying this heterogeneous disease.
In conclusion, genetic features associated with a different outcome were identified by genome-wide SNP-based array-CGH. When confirmed in other series, loss of 8p might highlight a group of patients with worse outcome when treated with R-CHOP-21 and characterized by a series of concomitant additional aberrations such as 17p and 15q losses. By applying unsupervised clustering, a distinct subgroup of patients characterized by a heterogeneous genomic profile, high prevalence of HCV infection, BM involvement and poor outcome with R-CHOP-21 could be observed. This subgroup deserves to be better characterized in order to design ad hoc therapeutic strategies.
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